Personalis (PSNL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 16, 2025, to be held virtually at 9:00 a.m. Pacific Time.
Shareholders are encouraged to review proxy materials and vote by May 15, 2025, 11:59 PM ET.
Voting matters and shareholder proposals
Election of two directors: A. Blaine Bowman and Karin Eastham, both recommended by the board.
Ratification of BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2025.
Advisory vote on executive compensation for named executive officers.
Proxyholders authorized to vote on other business arising at the meeting.
Board of directors and corporate governance
Board recommends all proposals, including director nominees and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Personalis
- Clinical test volume soared nearly 400% in 2025, with 2026 revenue guided to $78–$80 million.PSNL
Q4 202527 Feb 2026 - Ultra-sensitive ctDNA testing detects cancer recurrence and therapy response earlier than current methods.PSNL
Status Update3 Feb 2026 - Q2 revenue up 35% year-over-year, guidance raised, net loss narrowed, but risks remain.PSNL
Q2 20242 Feb 2026 - Q3 revenue up 41% year-over-year, biopharma surges, and cash runway extends to 2027.PSNL
Q3 202416 Jan 2026 - 14M shares from a $50M private placement registered for resale; no proceeds to the company.PSNL
Registration Filing16 Dec 2025 - 3.5M shares registered for resale after $17.7M private placement with Tempus AI, Inc.PSNL
Registration Filing16 Dec 2025 - 2024 revenue up 15% to $84.6M; net loss narrows; partnerships and MRD drive outlook.PSNL
Q4 20241 Dec 2025 - Board recommends voting for director nominees, auditor ratification, and executive pay approval.PSNL
Proxy Filing1 Dec 2025 - Clinical test volumes surged, but biopharma delays and risks drove lower revenue and guidance.PSNL
Q2 202523 Nov 2025